FDA Cleared Blood Lead Testing System Displayed at AACC
|
By LabMedica International staff writers Posted on 27 Jul 2015 |
US Food and Drug Administration (FDA) 510(k) clearance has been given for a new compact, relatively low cost analyzer to quantify lead levels in blood.
The “LeadCare Plus” clinical lead analyzer from Magellan Diagnostics (Billerica, MA, USA) offers simple-to-perform lead analysis with a compact footprint that makes blood lead testing accessible and practical for labs of any size. With dimensions smaller than a laptop, single-use consumables, and electronic calibration, the system is easy to implement even in space- and resource-constrained labs. The LeadCare Plus system is based on technology developed by Magellan Diagnostics that has been in clinical use for nearly two decades.
Blood lead testing is a critical preventative service: symptoms of lead exposure are nonspecific and subclinical, so a routine blood test is often the only way to identify exposure. According to the Centers for Disease Control and Prevention (CDC), there are over half a million children just in the USA still affected with elevated blood lead levels. Without early detection, elevated blood lead levels can impair cognition, reduce IQ, and cause attention-deficit disorders.
Amy Winslow, president, Magellan Diagnostics, said, "We are pleased that the FDA has cleared the LeadCare Plus System. Our mission is to help expand access to blood lead testing by offering a solution for every setting. With our other products CLIA-waived LeadCare II for point-of-care testing and LeadCare Ultra for high throughput lab analysis, LeadCare Plus completes this offering by providing a low capital cost system that gives even small labs the opportunity to bring this test in-house."
All three products will be on display during AACC 2015 (July 26–30; Atlanta, GA, USA) Clinical Lab Expo, Booth 3254.
Related Links:
Magellan Diagnostics
American Association for Clinical Chemistry (AACC)
AACC 2015 Annual Meeting & Clinical Lab Expo
The “LeadCare Plus” clinical lead analyzer from Magellan Diagnostics (Billerica, MA, USA) offers simple-to-perform lead analysis with a compact footprint that makes blood lead testing accessible and practical for labs of any size. With dimensions smaller than a laptop, single-use consumables, and electronic calibration, the system is easy to implement even in space- and resource-constrained labs. The LeadCare Plus system is based on technology developed by Magellan Diagnostics that has been in clinical use for nearly two decades.
Blood lead testing is a critical preventative service: symptoms of lead exposure are nonspecific and subclinical, so a routine blood test is often the only way to identify exposure. According to the Centers for Disease Control and Prevention (CDC), there are over half a million children just in the USA still affected with elevated blood lead levels. Without early detection, elevated blood lead levels can impair cognition, reduce IQ, and cause attention-deficit disorders.
Amy Winslow, president, Magellan Diagnostics, said, "We are pleased that the FDA has cleared the LeadCare Plus System. Our mission is to help expand access to blood lead testing by offering a solution for every setting. With our other products CLIA-waived LeadCare II for point-of-care testing and LeadCare Ultra for high throughput lab analysis, LeadCare Plus completes this offering by providing a low capital cost system that gives even small labs the opportunity to bring this test in-house."
All three products will be on display during AACC 2015 (July 26–30; Atlanta, GA, USA) Clinical Lab Expo, Booth 3254.
Related Links:
Magellan Diagnostics
American Association for Clinical Chemistry (AACC)
AACC 2015 Annual Meeting & Clinical Lab Expo
Latest AACC 2015 News
- Automated Molecular Diagnostics System Presented at AACC 2015
- Portable Molecular Diagnostics System Unveiled At 2015 AACC
- Expanded Steroid Control Launched at the 2015 AACC Annual Meeting
- Innovative New Technology to Provide Plastic-Exterior Components with Glass Interior, Presented at AACC 2015
- Eco-Friendly Immunoassay Reagents Featured at AACC 2015
- Low Cost Point-of-Care DNA Amplification Test for Chlamydia Infection Demonstrated at the 2015 AACC Annual Meeting
- Inexpensive Multipurpose Point-of-Care Analyzer Unveiled at 2015 AACC Annual Meeting
- State-of-the-Art Automated Laboratory Systems Highlighted at the 2015 AACC Annual Meeting
- Siemens Showcases Multiple New IVD Solutions at AACC 2015
- New HPLC Quadruples Clinical Throughput Capabilities, Displayed at AACC 2015
- Diagnostic Test that Measures Active Renin in Hypertension Displayed at the 2015 AACC Annual Meeting
- Hair Testing May Offer Insights into Asthma-Related Complications in Pregnancy
- Two Newly Developed Tests May Better Diabetes Diagnosis and Monitoring
- CE Marking of Theranostic Monitoring Test Announced at 2015 AACC Annual Meeting
- Ebola Rapid Lateral Flow Test Previewed at the 2015 AACC Annual Meeting
- AACC: Better Quality and Patient-Friendliness Needed in Direct Testing
Channels
Clinical Chemistry
view channel
Blood Test Could Predict and Identify Early Relapses in Myeloma Patients
Multiple myeloma is an incurable cancer of the bone marrow, and while many patients now live for more than a decade after diagnosis, a significant proportion relapse much earlier with poor outcomes.... Read more
Compact Raman Imaging System Detects Subtle Tumor Signals
Accurate cancer diagnosis often depends on labor-intensive tissue staining and expert pathological review, which can delay results and limit access to rapid screening. These conventional methods also make... Read moreMolecular Diagnostics
view channel
Sepsis Test Demonstrates Strong Performance in Post-Cardiac Surgery Patients
Sepsis is difficult to diagnose accurately in patients recovering from major surgery, as infection-related symptoms often overlap with non-infectious systemic inflammatory responses. This challenge is... Read more
Next-Gen Automated ELISA System Elevates Laboratory Performance
A next-generation automated ELISA system is designed to elevate laboratory performance through advanced workflow automation, enhanced connectivity, and a modernized user experience. DYNEX Technologies... Read more
At-Home Blood Tests Accurately Detect Key Alzheimer's Biomarkers
Diagnosing Alzheimer’s disease typically relies on brain scans or spinal fluid tests, which are invasive, costly, and difficult to access outside specialist clinics. These barriers have limited large-scale... Read more
Blood Test Combined with MRI Brain Scans Reveals Two Distinct Multiple Sclerosis Types
Multiple sclerosis (MS) affects more than 2.8 million people worldwide, yet predicting how the disease will progress in individual patients remains difficult. Current MS classifications are based on clinical... Read moreHematology
view channel
MRD Tests Could Predict Survival in Leukemia Patients
Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more
Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
Assessing disease severity in sickle cell disease (SCD) remains challenging, especially when trying to predict hemolysis, vascular injury, and risk of complications such as vaso-occlusive crises.... Read more
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read moreImmunology
view channel
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read more
Blood Test Could Identify Colon Cancer Patients to Benefit from NSAIDs
Colon cancer remains a major cause of cancer-related illness, with many patients facing relapse even after surgery and chemotherapy. Up to 40% of people with stage III disease experience recurrence, highlighting... Read moreMicrobiology
view channel
New UTI Diagnosis Method Delivers Antibiotic Resistance Results 24 Hours Earlier
Urinary tract infections affect around 152 million people every year, making them one of the most common bacterial infections worldwide. In routine medical practice, diagnosis often relies on rapid urine... Read more
Breakthroughs in Microbial Analysis to Enhance Disease Prediction
Microorganisms shape human health, ecosystems, and the planet’s climate, yet identifying them and understanding how they are related remains a major scientific challenge. Even with modern DNA sequencing,... Read morePathology
view channel
ADLM Updates Expert Guidance on Urine Drug Testing for Patients in Emergency Departments
Urine drug testing plays a critical role in the emergency department, particularly for patients presenting with suspected overdose or altered mental status. Accurate and timely results can directly influence... Read more
New Age-Based Blood Test Thresholds to Catch Ovarian Cancer Earlier
Ovarian cancer affects around one in 50 women during their lifetime, with roughly 7,000 diagnoses each year in the UK. The disease is often detected late because symptoms such as bloating, abdominal pain,... Read moreTechnology
view channel
Pioneering Blood Test Detects Lung Cancer Using Infrared Imaging
Detecting cancer early and tracking how it responds to treatment remains a major challenge, particularly when cancer cells are present in extremely low numbers in the bloodstream. Circulating tumor cells... Read more
AI Predicts Colorectal Cancer Survival Using Clinical and Molecular Features
Colorectal cancer is one of the most common and deadly cancers worldwide, and accurately predicting patient survival remains a major clinical challenge. Traditional prognostic tools often rely on either... Read moreIndustry
view channel
BD and Penn Institute Collaborate to Advance Immunotherapy through Flow Cytometry
BD (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) has entered into a strategic collaboration with the Institute for Immunology and Immune Health (I3H, Philadelphia, PA, USA) at the University... Read more





 assay.jpg)


